|drug2240||Observation of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings Wiki||1.00|
There is one clinical trial.
QuadraMune(TM) is a nutritional supplement which has previously been demonstrated to possess antiinflammatory and immune modulatory activity based on in vitro and pilot in vivo studies. The current clinical trial aims to assess in a 500 volunteer trial the efficacy of QuadraMune(TM) in reducing infection in individuals at high risk of COVID-19.
Description: Prevention of COVID-19 symptoms as recorded in a daily diaryMeasure: Prevention of COVID-19 Time: 12 Weeks
Description: Assessment of adverse events and serious adverse events will be performed.Measure: Safety as determined by presence or absence of Adverse Events and Serious Adverse Events Time: 12 Weeks
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports